Vesalius Research Center, VIB and KULeuven, Campus Gasthuisberg, Herestraat 49, Box 912, B-3000 Leuven, Belgium.
Eur Heart J. 2010 May;31(9):1132-41. doi: 10.1093/eurheartj/ehq053. Epub 2010 Mar 15.
Recent genetic studies identified the rs1333049 variant on chromosome 9p21 as a major susceptibility locus for coronary artery disease and myocardial infarction (MI). Here, we evaluated whether this variant also contributes to recurrent MI or cardiac death following an acute coronary syndrome (ACS).
A total of 3247 patients with ACS enrolled in the Global Registry of Acute Coronary Events (GRACE) in three distinct populations (UK, Belgium and Poland) were prospectively followed for 6 months and genotyped for rs1333049, in addition to 3004 and 2467 healthy controls from the UK and Belgium. After having confirmed that the at-risk C allele of rs1333049 was associated with index ACS in the UK and Belgian populations, we found that the rs1333049 at-risk C allele was significantly and independently associated with recurrent MI [age- and gender-adjusted hazard ratio (HR) 1.48, CI = 1.00-2.19, P = 0.048; and multivariable-adjusted HR 1.47, CI = 0.99-2.18; P = 0.053] and with recurrent MI or cardiac death (age- and gender-adjusted HR 1.58, CI = 1.00-2.48; P = 0.045; and multivariable adjusted HR 1.49, CI = 1.03-1.98; P = 0.028) within 6 months after an index ACS. Inclusion of rs1333049 into the GRACE risk score significantly improved classification for recurrent MI or cardiac death (P = 0.040), as calculated by the integrated discrimination improvement method.
In this large observational study, the 9p21 variant was independently associated with adverse cardiac outcome after ACS.
最近的遗传研究发现,9 号染色体上的 rs1333049 变异是冠心病和心肌梗死(MI)的主要易感基因座。在这里,我们评估了该变体是否也会导致急性冠状动脉综合征(ACS)后再发性 MI 或心脏性死亡。
共有 3247 例 ACS 患者在三个不同人群(英国、比利时和波兰)的全球急性冠状动脉事件注册(GRACE)中进行前瞻性随访 6 个月,并对 rs1333049 进行了基因分型,另外还对英国和比利时的 3004 例和 2467 例健康对照者进行了基因分型。在确认 rs1333049 的风险 C 等位基因与英国和比利时人群的指数 ACS 相关后,我们发现 rs1333049 的风险 C 等位基因与再发性 MI 显著且独立相关[年龄和性别调整的危险比(HR)1.48,95%置信区间(CI)为 1.00-2.19,P = 0.048;多变量调整的 HR 为 1.47,95%CI = 0.99-2.18;P = 0.053],与再发性 MI 或心脏性死亡(年龄和性别调整的 HR 为 1.58,95%CI = 1.00-2.48;P = 0.045;多变量调整的 HR 为 1.49,95%CI = 1.03-1.98;P = 0.028)相关在 ACS 后 6 个月内。通过综合鉴别改善方法计算,将 rs1333049 纳入 GRACE 风险评分可显著改善再发性 MI 或心脏性死亡的分类(P = 0.040)。
在这项大型观察性研究中,9p21 变异与 ACS 后不良心脏结局独立相关。